Side effects of alpha interferon in chronic hepatitis C
- PMID: 9305675
- DOI: 10.1002/hep.510260720
Side effects of alpha interferon in chronic hepatitis C
Abstract
Alpha interferons have been used widely to treat chronic hepatitis C virus infection. These include recombinant interferons, purified natural leukocyte, and lymphoblastoid interferons. Alpha interferon is administered by subcutaneous or intramuscular injection either daily or three times weekly for a period of 6 to as long as 24 months. A wide array of adverse effects of alpha interferon have been described. Several side effects such as fever, headache fatigue, arthralgias, and myalgias are common, especially with the initial injections. These early side effects of interferon are predictable and are encountered in the majority of patients. These may not require dose modification, but can be problematic for a significant proportion of patients. Other adverse events effects may require dose modification or even discontinuation of therapy in 2% to 10% of patients. Neuropsychiatric side effects such as depression and irritability can be most troublesome; their mechanisms are not well understood. Granulocytes, platelets, and red blood cell counts decrease during treatment, but the decreases are usually mild, although they can be dose limiting if cell counts are low initially. Interferon has important immunomodulatory properties, and treatment can induce autoimmune phenomena, the most frequent being autoimmune thyroiditis with either hypothyroidism or hyperthyroidism, especially in predisposed patients. Other autoimmune disease can be aggravated by interferon therapy. Severe and even life-threatening side effects of interferon occur in 0.1% to 1% of patients; these include thyroid, visual, auditory, renal, and cardiac impairment, and pulmonary interstitial fibrosis. Some of these side effects may be irreversible. Higher doses of interferon (above 5 million units three times weekly) cause higher rates of adverse events than standard doses. Contraindications to alpha interferon have been recognized.
Similar articles
-
Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.Eur J Gastroenterol Hepatol. 2007 Feb;19(2):119-23. doi: 10.1097/01.meg.0000252626.73172.f3. Eur J Gastroenterol Hepatol. 2007. PMID: 17272996 Clinical Trial.
-
Therapy of hepatitis C: re-treatment with alpha interferon.Hepatology. 1997 Sep;26(3 Suppl 1):137S-142S. doi: 10.1002/hep.510260724. Hepatology. 1997. PMID: 9305679 Review.
-
[Hypothyroidism as a complication of the treatment of hepatitis C with interferon].An Med Interna. 1996 Sep;13(9):438-40. An Med Interna. 1996. PMID: 9132035 Spanish.
-
[The neuropsychiatric side effects of the interferon therapy in patients with chronic hepatitis B and C].Pol Merkur Lekarski. 1999 Jul;7(37):8-11. Pol Merkur Lekarski. 1999. PMID: 10522402 Polish.
-
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis.Biomed Pharmacother. 1999 Jun;53(5-6):242-54. doi: 10.1016/S0753-3322(99)80095-X. Biomed Pharmacother. 1999. PMID: 10424246 Review.
Cited by
-
Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.Medicine (Baltimore). 2016 May;95(21):e3782. doi: 10.1097/MD.0000000000003782. Medicine (Baltimore). 2016. PMID: 27227948 Free PMC article.
-
Chronic hepatitis C virus and celiac disease, is there an association?Dig Dis Sci. 2008 Jan;53(1):256-61. doi: 10.1007/s10620-007-9851-z. Epub 2007 Jun 5. Dig Dis Sci. 2008. PMID: 17549632
-
Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment.Synapse. 2014 Nov;68(11):548-55. doi: 10.1002/syn.21766. Epub 2014 Aug 4. Synapse. 2014. PMID: 25043294 Free PMC article.
-
Effects of COVID-19 on the Musculoskeletal System: Clinician's Guide.Orthop Res Rev. 2021 Sep 21;13:141-150. doi: 10.2147/ORR.S321884. eCollection 2021. Orthop Res Rev. 2021. PMID: 34584465 Free PMC article. Review.
-
Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial.Clin Drug Investig. 2023 Jun;43(6):447-461. doi: 10.1007/s40261-023-01278-3. Epub 2023 Jun 22. Clin Drug Investig. 2023. PMID: 37347370 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical